Progress in Spondylarthritis. Mechanisms of new bone formation in spondyloarthritis
Top Cited Papers
Open Access
- 1 January 2009
- journal article
- review article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 11 (2) , 221
- https://doi.org/10.1186/ar2642
Abstract
Targeted therapies that neutralize tumour necrosis factor are often able to control the signs and symptoms of spondyloarthritis. However, recent animal model data and clinical observations indicate that control of inflammation may not be sufficient to impede disease progression toward ankylosis in these patients. Bone morphogenetic proteins and WNTs (wingless-type like) are likely to play an important role in ankylosis and could be therapeutic targets. The relationship between inflammation and new bone formation is still unclear. This review summarizes progress made in our understanding of ankylosis and offers an alternative view of the relationship between inflammation and ankylosis.This publication has 44 references indexed in Scilit:
- Treatment recommendations for psoriatic arthritisAnnals of the Rheumatic Diseases, 2009
- Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2009
- Activation of β-Catenin Signaling in Articular Chondrocytes Leads to Osteoarthritis-Like Phenotype in Adult β-Catenin Conditional Activation MiceJournal of Bone and Mineral Research, 2009
- Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatmentArthritis Research & Therapy, 2008
- The relationship between inflammation and new bone formation in patients with ankylosing spondylitisArthritis Research & Therapy, 2008
- Inhibition of β‐catenin signaling in articular chondrocytes results in articular cartilage destructionArthritis & Rheumatism, 2008
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IArthritis & Rheumatism, 2007
- Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2Arthritis & Rheumatism, 2007
- Developmental regulation of the growth plateNature, 2003
- Classification of inflammatory arthritis by enthesitisThe Lancet, 1998